John Nesbitt - Assessment of systemic exposure following oral administration of mesalamine as an 800 mg tablet (4.8 g/day) or a 400 mg tablet (2.4 g/day): analysis of combined data from two randomized clinical trials in patients with ulcerative colitis

Version 1

      Publication Details (including relevant citation   information):

      W.J. Sandborn, C.D. Stone, K.A. Papadakis, F.O. Ajayi,   J.D. Nesbitt, G.   Regalli

      Poster presentation at World Congress of Gastroenterology 2005,   Montreal, Canada, 9/12‑9/14, 2005 and at United European   Gastroenterology Week 2005, Copenhagen, Denmark, 10/15‑10/19,   2005.


      Address (URL): http://